Bone disease in hemodialysis patients with particular reference to the effect of fluoride.
Forty-one patients on our chronic hemodialysis program were assessed for the degree of progression of bone disease over an average period of 46 months. Seven patients were using a fluoridated dialysate. Four of these seven patients developed a marked increase in osteoid as judged by bone biopsy, while in the nonfluoridated group the amount of osteoid remained within normal limits.In the absence of fluoride, although osteitis fibrosa occurred, it was reversible in 10 out of 12 cases by dihydrotachysterol treatment, and overall there was no evidence of progression of bone disease at the end of the study period.
D000328:Adult; D000469:Alkaline Phosphatase / Q000032:analysis; D001706:Biopsy; D001842:Bone and Bones / Q000473:pathology; D004097:Dihydrotachysterol / Q000627:therapeutic use; D005260:Female; D005357:Fibrous Dysplasia of Bone / Q000139:chemically induced* / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000209:etiology / Q000473:pathology; D005385:Fingers / Q000473:pathology; D005459:Fluorides / Q000009:adverse effects*; D005921:Glomerulonephritis / Q000000981:diagnostic imaging / Q000201:enzymology / Q000628:therapy*; D006801:Humans; D008297:Male; D011859:Radiography; D006435:Renal Dialysis / Q000009:adverse effects*
D000469:Alkaline Phosphatase; D005459:Fluorides; D004097:Dihydrotachysterol